...
首页> 外文期刊>Biochimica et biophysica acta. Biomembranes >Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105)
【24h】

Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105)

机译:使用针对人内皮糖蛋白的单链Fv片段将免疫脂质体靶向内皮细胞(CD105)

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

We generated immunoliposomes targeting proliferating endothelial cells by chemically coupling a single-chain Fv fragment (scFv A5) directed against human endoglin to the liposomal surface. For this purpose, we introduced an additional cysteine residue at the C-terminus of the scFv fragment. This scFv' fragment was expressed in soluble form in bacteria and allowed for a site-directed coupling to sulfhydryl-reactive lipids incorporated into the lipid bilayer. The immunoliposomes (ILA5) showed rapid and strong binding to human endoglin-expressing endothelial cells (HUVEC, HDMEC), while no binding was observed with various endoglin-negative cell lines and blood lymphocytes. In vitro, ILA5 were stable for several hours in serum- or plasma-containing medium. Incubation of endothelial cells with ILA5 at 37 ℃ led to increased binding and internalisation of the liposomes as evidenced by a perinuclear accumulation. In vitro, doxorubicin-loaded ILA5 showed an increased cytotoxicity towards endothelial cells compared to untargeted liposomes and free doxorubicin. Since the vasculature of tumours is easily accessible to drug carrier systems, the described endothelial cell-specific immunoliposomes may be useful for the development of efficacious and safe vascular targeting agents in cancer therapy.
机译:我们通过将针对人内皮糖蛋白的单链Fv片段(scFv A5)化学偶联至脂质体表面,从而生成了靶向增殖内皮细胞的免疫脂质体。为此,我们在scFv片段的C末端引入了一个额外的半胱氨酸残基。该scFv'片段以可溶形式在细菌中表达,并允许与掺入脂质双层的巯基反应性脂质进行定点偶联。免疫脂质体(ILA5)与表达人内皮糖蛋白的内皮细胞(HUVEC,HDMEC)表现出快速而牢固的结合,而各种内皮糖蛋白阴性细胞系和血液淋巴细胞均未观察到结合。在体外,ILA5在含血清或血浆的培养基中稳定数小时。内皮细胞在37℃下与ILA5一起孵育会导致脂质体的结合和内在化,这在核周积累中得到了证明。在体外,与未靶向脂质体和游离阿霉素相比,阿霉素负载的ILA5对内皮细胞的细胞毒性增加。由于肿瘤的脉管系统易于通过药物载体系统进入,因此所描述的内皮细胞特异性免疫脂质体可用于开发癌症治疗中有效且安全的血管靶向剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号